About Abeona Therapeutics Inc.
Working together to find a cure
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cleveland, OH
- Founded
- 2015
- Company type
- Public Company
- Company profile name
- Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Specialties
- Gene Therapy
- Biotechnology
- Cell Therapy
- Rare Disease
- Epidermolysis Bullosa
- Pediatric Rare Diseases
- and manufacturing
Company locations
6555 Carnegie Avenue, Cleveland, OH 44103, US
6700 Euclid Ave, Cleveland, OH 44106, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Medical Device
- Biotechnology
- Genetics
- Manufacturing
On LinkedIn
- Followers
- 22,319
- People linked to this company
- 237
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
429,700,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.